🇺🇸 FDA
Patent

US 10407679

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

granted A61KA61K31/713A61P

Quick answer

US patent 10407679 (Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
43
CPC classes
A61K, A61K31/713, A61P, A61P1/16, A61P1/18